An Australian technology start-up, which has developed a test to screen embryos for thousands of genetic diseases, has ditched its plan to list on the Nasdaq, after the chairman blamed US President Donald Trump’s tariff chaos for spooking investors.

GenEmbryomics had been preparing for its float for 18 months, but failed to raise the full $US5.3 million ($8.4 million) for its initial public offering by April 8, a date that coincided with the bottom of the sharp global sharemarket correction triggered by Trump’s tariff policies.